Product: A Medical Food for Managing ADHD Symptoms Developers: The Enzymotec Research and Development Team, led by Dr. Ariel Katz Company: Enzymotec Start of Development: 2005
Attention Deficit Hyperactivity Disorders (ADHD) have attracted significant public and medical attention in recent years, and attempts to find different treatments have intensified with the increasing scope of diagnosis. Current estimates indicate that 5-12 percent of children today are diagnosed as suffering from the disorder worldwide.
The most common treatment for ADHD is by means of medicines from the stimulant family (such as Ritalin). This treatment has proven to be extremely efficient, although its influence is limited to a period of several hours and, in some cases, is accompanied by side effects.
Enzymotec was founded in 1998 by Dr. Ariel Katz with the aim of developing advanced nutritional solutions including bioactive ingredients, medical foods, and dietary supplements. In 2005, the company’s research and development team identified a connection between low blood levels of certain fats and ADHD, and viewed this finding as an opportunity to develop a solution in the form of a unique medical food that would enable them to significantly improve the symptoms of ADHD.
In 2006, the company developed the Vayarin medical composition, the efficiency of which was demonstrated in clinical trials with children suffering from ADHD. Vayarin presents a holistic, long-lasting solution for children suffering from attention deficit and hyperactivity disorders with an excellent safety profile. Vayarin’s effect is sustained throughout the day and is extremely beneficial for patients with emotional dysregulation (prone to angry and emotional outbursts).
Since 2010, Vayarin has been marketed in Israel by TEVA under the trade name Zoom. Enzymotec’s innovative series of medical food products, led by Vayarin, was launched worldwide in 2011.
Vayarin generates annual income of approximately 10 million US dollars, and tens of thousands of children around the world benefit from its advantages. The company is presently launching a product aimed at an expanded age range of ADHD patients, so that Vayarin’s benefits will also be available to teenagers and
adults.
